Chimeric antigen receptor T-cell therapies - Tmunity Therapeutics

Drug Profile

Chimeric antigen receptor T-cell therapies - Tmunity Therapeutics

Latest Information Update: 01 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tmunity Therapeutics
  • Developer Tmunity Therapeutics; University of Pennsylvania
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Solid tumours
  • Preclinical Autoimmune disorders; HIV infections

Most Recent Events

  • 23 Jan 2018 Tmunity Therapeutics intends to file additional IND application in 2018
  • 23 Jan 2018 Tmunity Therapeutics collaborates with the University of Pennsylvania for CAR T-cell immunotherapeutics
  • 23 Jan 2018 Preclinical trials in Autoimmune disorders in USA (Parenteral) (Tmunity Therapeutics website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top